A5101784505- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Diagnosis and treatment of tuberculosis
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- Inflammatory Bowel Disease
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- PARP inhibition in cancer therapy
- Genetic factors in colorectal cancer
- Tuberculosis Research and Epidemiology
- Helicobacter pylori-related gastroenterology studies
- Mycobacterium research and diagnosis
- Microscopic Colitis
- Histone Deacetylase Inhibitors Research
- RNA modifications and cancer
- BRCA gene mutations in cancer
- Metastasis and carcinoma case studies
Hunan Cancer Hospital
2016-2025
Peking Union Medical College Hospital
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2018-2025
Dalian University of Technology
2025
Central South University
2003-2023
West China Hospital of Sichuan University
2018
Samsung Medical Center
2018
Seoul National University Hospital
2018
Cancer Research Institute
2018
Aichi Cancer Center
2018
Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy of pyrotinib versus lapatinib, both combination with capecitabine, women human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer open-label, multicenter, randomized II study.Chinese patients HER2-positive relapsed or previously treated taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400...
Abstract Background The standard first‐line treatment for human epidermal growth factor receptor 2 (HER2)‐positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti‐HER2 bispecific antibody, docetaxel in HER2‐positive cancer. Methods open‐label, single‐arm, phase II enrolled patients with 19 centers across China from December 30, 2019 May 27, 2021. Patients were administered KN026...
Patients selected to receive neoadjuvant chemotherapy (NAC) are usually those at higher risk of relapse, and there is a need find better therapeutic options for these patients.
Abstract Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, docetaxel compared with placebo, for untreated HER2 positive metastatic breast cancer. Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial. Setting 40 centres in China between 6 May 2019 17 January 2022. Participants 590 female patients (median age 52 (interquartile range 46-58) years) Interventions Eligible...
PURPOSE The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS Randomized trials were conducted at 12 centers in China from August 22, 2017, September 24, 2021, and the final follow-up date was 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic setting enrolled. Participants 1:1 assigned...
The objective of this study was to evaluate the efficacy and safety eribulin monotherapy, relative vinorelbine, in Chinese women with locally recurrent/metastatic breast cancer (MBC).This phase III open-label, randomised, parallel-group, multicentre clinical trial enrolled patients recurrent or MBC who had 2-5 prior chemotherapy regimens, including an anthracycline taxane) from September 26, 2013, May 19, 2015. Women were randomised 1:1 receive (1.4 mg/m2, intravenously, on day 1 8)...
PurposeIn cancer patients, tumor gene mutations contribute to drug resistance and treatment failure. In patients with metastatic breast (MBC), these increase after multiline treatment, thereby decreasing efficiency. The aim of this study was evaluate mutation patterns in MBC predict disease progression.MethodA total 68 who had received were recruited. Circulating DNA (ctDNA) evaluated compared among hormone receptor (HR)/human epidermal growth factor 2 (HER2) subgroups.ResultsThe baseline...
Bronchoscopy inspection, as a follow-up procedure next to the radiological imaging, plays key role in diagnosis and treatment design for lung disease patients. When performing bronchoscopy, doctors have make decision immediately whether perform biopsy. Because biopsies may cause uncontrollable life-threatening bleeding of tissue, thus need be selective with biopsies. In this paper, help more on provide second opinion diagnosis, we propose computer-aided (CAD) system diseases, including...
1001 Background: Pyrotinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor, showed promising anti-tumour activity and acceptable tolerability in patients with HER2+ metastatic breast cancer (MBC) phase 1/2 trials. Methods: This double-blinded, multicentre, randomised 3 trial was conducted Chinese MBC previously treated taxanes trastuzumab. Patients were randomly assigned (2:1) to receive 400 mg pyrotinib or placebo orally once daily for 21-day cycles combination capecitabine...
Patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have poor prognoses. Pyrotinib has shown promising antitumor activity in MBC to improve progression-free survival (PFS). However, findings based on real-world data analyze whether pyrotinib affects overall (OS) remain scarce.This study is an exploratory analysis of brain metastasis (BM) and the final update our preceding 168 patients HER2+ MBC. PFS, OS, tumor mutation burden (TMB), clinical benefit rate (CBR), response (ORR)...
Human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification is an important predictive biomarker for identifying patients with breast cancer, who may benefit from HER2-targeted therapy. However, little known about the molecular landscape and efficacy of therapy in HER2-mutated metastatic cancer. We analysed HER2 mutation features 1184 invasive In addition, a single-arm, prospective, phase-II study (NCT03412383) pyrotinib was conducted patient...
Background: Pyrotinib, an irreversible pan-ERBB inhibitor, has shown promising antitumour activity, and acceptable tolerability. This research was conducted to evaluate the actual use effectiveness of pyrotinib in China, therefore, contributed solve problem real-world data scarcity. Methods: In this retrospective study, 168 patients who received treatment for HER2-positive metastatic breast cancer (MBC) Hunan Province from June 2018 August 2019 were included. Progression-free survival (PFS),...
1020 Background: ARX788 is a next-generation ADC of HER2 monoclonal antibody site-specifically conjugated with Amberstatin 269, potent cytotoxic tubulin inhibitor. Here we report the interim result from this seamless phase II/III trial in patients who progressed on trastuzumab based therapy. Methods: This randomized study was conducted HER2+ (FISH+ or IHC3+) ABC 85 centers China. Patients unresectable metastatic breast cancer pretreated and taxane were 1:1 to receive (1.5mg/kg, IV, Q3W)...
With the increasing development of transportation and rise motor vehicle ownership, problem polycyclic aromatic hydrocarbons （PAHs） pollution in roadside farmland soils cannot be ignored. This study examined levels, composition, sources, health risks PAHs along with highways China, based on 16 years soil data. The results indicated that median concentration China's was 490.15 μg·kg-1, a range 86.40 to 3 568.00 μg·kg-1. content PAH monomers ranged from 5.55 47.39 μg·kg-1 （in median）, highest...
Image‐based screening is an efficient drug discovery strategy. Combining high‐content (HCS) with artificial intelligence efficiently detects drug‐induced cellular phenotypes from a large pool of compounds. However, previous studies primarily focus on cell classification and cannot interpret models using morphological features. Additionally, the existing morphology‐based use only few features, which accurately characterize phenotypic perturbations. Herein, π‐PhenoDrug, deep learning‐based...
Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real-world data are lacking, the present research was conducted to evaluate actual use and effectiveness trastuzumab in real world China.Inpatients with HER2 invasive cancer from 13 hospitals Eastern China (2010-2015, n = 1,139) were included this study. We aimed assess potential efficacy research.Of 1,017 patients early stage (EBC), 40.5% (412/1,017) received therapy....
Endocrine therapy and cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) are standard treatment options for hormone receptor positive (HR+)/human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (MBC). However, the efficacy of subsequent therapies after CDK4/6i-based is unclear. This study aimed to examine physician practice patterns outcomes administered progression on palbociclib in clinical practice.The included 200 patients with HR+/HER2- MBC who underwent...
The effectiveness of the mammalian target rapamycin (mTOR) inhibitor everolimus in premenopausal women with hormone receptor (HR)-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving selective estrogen modulators (SERMs) is unknown.To compare plus letrozole vs alone HR-positive/ERBB2-negative SERMs.The Everolimus Trial for Advanced Premenopausal Breast Cancer (MIRACLE) was a multicenter, open-label phase 2 randomized clinical trial as first-line...
1003 Background: Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine showed clinically meaningful benefits and acceptable tolerability in patients (pts) with HER2+ metastatic breast cancer (MBC) phase 1 2 studies. Methods: This open-label, multicenter, randomized 3 study enrolled MBC pts after trastuzumab taxanes, and/or anthracyclines. Up to two prior lines of chemotherapy (chemo) for disease were allowed. Pts randomly assigned (1:1) receive pyrotinib 400 mg or lapatinib 1250...
Abstract The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who had received ≤2 lines setting. Here, we report pre-specified analyses data from Asian (China, Japan, Korea Taiwan) study. All were randomized 2:1 to tablets or...